1. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir
- Author
-
Christine J. Weegink, Peter L.M. Jansen, Hans L. Zaaijer, Richard Molenkamp, Valeska Terpstra, Hendrik W. Reesink, Marcel Beld, M. Koot, Vincent Rijckborst, Louis Jansen, R. Bart Takkenberg, Annikki de Niet, Harry L.A. Janssen, Marcel G. W. Dijkgraaf, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Other departments, AII - Amsterdam institute for Infection and Immunity, Medical Microbiology and Infection Prevention, Clinical Research Unit, and Experimental Immunology
- Subjects
Adult ,Male ,Hepatitis B virus ,HBsAg ,medicine.medical_specialty ,Genotype ,Biopsy ,Organophosphonates ,Hepatitis b surface antigen ,Antiviral Agents ,Gastroenterology ,Polyethylene Glycols ,Young Adult ,Hepatitis B, Chronic ,Chronic hepatitis ,Pegylated interferon ,Internal medicine ,Adefovir ,Humans ,Medicine ,Pharmacology (medical) ,Aged ,Pharmacology ,Hepatitis B Surface Antigens ,business.industry ,Adenine ,Interferon-alpha ,virus diseases ,Middle Aged ,Viral Load ,Virology ,Recombinant Proteins ,digestive system diseases ,Treatment Outcome ,Infectious Diseases ,Liver ,Drug Therapy, Combination ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
Background In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir. Methods We treated 92 chronic hepatitis B patients (44 hepatitis B e antigen [HBeAg]-positive and 48 HBeAg-negative) with HBV DNA>100,000 copies/ml (>17,182 IU/ ml) with PEG-IFN and adefovir for 48 weeks and followed them up for 2 years. Baseline markers for HBeAg loss, combined response (HBeAg negativity, HBV DNA levels ≤2,000 IU/ml and alanine aminotransferase [ALT] normalization) and hepatitis B surface antigen (HBsAg) loss were evaluated. Results Two years after the end of treatment, rates of HBeAg loss and HBsAg loss in HBeAg-positive patients were 18/44 (41%) and 5/44 (11%), respectively. In HBeAg-negative patients, rates of combined response and HBsAg loss were 12/48 (25%) and 8/48 (17%), respectively. HBeAg-negative patients with HBsAg loss had lower baseline HBsAg levels than those without HBsAg loss (mean HBsAg 2.35 versus 3.55 log10 IU/ml; PConclusions With combination therapy of PEG-IFN and adefovir for 48 weeks, a high rate of HBsAg loss was observed in both HBeAg-positive (11%) and HBeAg-negative (17%) patients 2 years after treatment ended. In HBeAg-negative patients, a low baseline HBsAg level was a strong predictor for HBsAg loss.
- Published
- 2013
- Full Text
- View/download PDF